Login to Your Account

Alectos to Study Alzheimer's Target in Merck $289M Deal

By Catherine Hollingsworth

Thursday, August 12, 2010
Alectos Therapeutics Inc. will receive up to $289 million in an up-front fee and milestone payments under a collaboration with Merck & Co. to study a potential non-amyloid approach to treat Alzheimer's disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription